Mersana Therapeutics, Inc. (MRSN)
- Previous Close
0.3401 - Open
0.3613 - Bid 0.2905 x 200
- Ask 0.4748 x 200
- Day's Range
0.3605 - 0.4240 - 52 Week Range
0.2590 - 2.8300 - Volume
10,121,986 - Avg. Volume
3,099,681 - Market Cap (intraday)
47.983M - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5900 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.29
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
www.mersana.comRecent News: MRSN
View More
Performance Overview: MRSN
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRSN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRSN
View MoreValuation Measures
Market Cap
47.98M
Enterprise Value
-29.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.40
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-217.63%
Return on Assets (ttm)
-30.90%
Return on Equity (ttm)
--
Revenue (ttm)
34.01M
Net Income Avi to Common (ttm)
-74.01M
Diluted EPS (ttm)
-0.5900
Balance Sheet and Cash Flow
Total Cash (mrq)
102.29M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-36.67M